126 related articles for article (PubMed ID: 38542429)
21. BCL-2 protein family: attractive targets for cancer therapy.
Kaloni D; Diepstraten ST; Strasser A; Kelly GL
Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
[TBL] [Abstract][Full Text] [Related]
22. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
Griffioen MS; de Leeuw DC; Janssen JJWM; Smit L
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884517
[TBL] [Abstract][Full Text] [Related]
23. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Hoeller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
Eur J Cancer; 2022 Jul; 170():256-284. PubMed ID: 35623961
[TBL] [Abstract][Full Text] [Related]
24. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Höller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
Eur J Cancer; 2022 Jul; 170():236-255. PubMed ID: 35570085
[TBL] [Abstract][Full Text] [Related]
25. Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Winkler M; Friedrich J; Boedicker C; Dolgikh N
Transl Oncol; 2022 Feb; 16():101313. PubMed ID: 34906889
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
[TBL] [Abstract][Full Text] [Related]
27. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
Diepstraten ST; Anderson MA; Czabotar PE; Lessene G; Strasser A; Kelly GL
Nat Rev Cancer; 2022 Jan; 22(1):45-64. PubMed ID: 34663943
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
29. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
[TBL] [Abstract][Full Text] [Related]
30. Targeting MCL-1 in cancer: current status and perspectives.
Wang H; Guo M; Wei H; Chen Y
J Hematol Oncol; 2021 Apr; 14(1):67. PubMed ID: 33883020
[TBL] [Abstract][Full Text] [Related]
31. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
32. It's time to die: BH3 mimetics in solid tumors.
Kehr S; Vogler M
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118987. PubMed ID: 33600840
[TBL] [Abstract][Full Text] [Related]
33. Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells.
Yu R; Lu Y; Yu R; Xie J; Zhou S
Cancer Manag Res; 2021; 13():953-963. PubMed ID: 33568941
[TBL] [Abstract][Full Text] [Related]
34. The BH3 mimetic (±) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro.
Haasler L; Kondadi AK; Tsigaras T; von Montfort C; Graf P; Stahl W; Brenneisen P
Arch Toxicol; 2021 Apr; 95(4):1349-1365. PubMed ID: 33523262
[TBL] [Abstract][Full Text] [Related]
35. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
36. Defining the susceptibility of colorectal cancers to BH3-mimetic compounds.
Luo MJ; Palmieri M; Riffkin CD; Sakthianandeswaren A; Djajawi TM; Hirokawa Y; Shuttleworth V; Segal DH; White CA; Nhu D; Lessene G; Lee M; Gibbs P; Huang DCS; Sieber OM; Gong JN
Cell Death Dis; 2020 Sep; 11(9):735. PubMed ID: 32913182
[TBL] [Abstract][Full Text] [Related]
37. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
Sarif Z; Tolksdorf B; Fechner H; Eberle J
Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
[TBL] [Abstract][Full Text] [Related]
38. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.
Mukherjee N; Amato CM; Skees J; Todd KJ; Lambert KA; Robinson WA; Van Gulick R; Weight RM; Dart CR; Tobin RP; McCarter MD; Fujita M; Norris DA; Shellman YG
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764384
[TBL] [Abstract][Full Text] [Related]
39. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Mukherjee N; Skees J; Todd KJ; West DA; Lambert KA; Robinson WA; Amato CM; Couts KL; Van Gulick R; MacBeth M; Nassar K; Tan AC; Zhai Z; Fujita M; Bagby SM; Dart CR; Lambert JR; Norris DA; Shellman YG
Cell Death Dis; 2020 Jun; 11(6):443. PubMed ID: 32513939
[TBL] [Abstract][Full Text] [Related]
40. BCL-w: apoptotic and non-apoptotic role in health and disease.
Hartman ML; Czyz M
Cell Death Dis; 2020 Apr; 11(4):260. PubMed ID: 32317622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
